DMT Therapy: Coming to a Clinic Near You?
DMT, or N, N-dimethyltryptamine is a powerful psychedelic. DMT, like its sister psychedelics (LSD, MDMA, psilocybin … and even marijuana), is a Schedule I controlled substance. So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” Indeed, DMT is the active ingredient in ayahuasca and has been used by indigenous communities in the Amazon for centuries; here, the past few decades have seen a resurgence in the use of DMT and/or ayahuasca ceremonies by non-indigenous persons.
Notwithstanding its dubious distinction as a Schedule I drug, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. This research—as with psilocybin, MDMA, ketamine, ibogaine etc.—is expanding rapidly as numerous neuropharmaceutical companies look to be among the first-to-market potentially revolutionary therapies.
Just last month, Small Pharma, a neuropharmaceutical company, announced that that it has been granted an Innovation Passport Designation by the U.K. Medicines and Healthcare Products Regulatory Agency for one of its DMT